FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152606916> ?p ?o ?g. }

• W2152606916 endingPage "7" @default.
• W2152606916 startingPage "1790" @default.
• W2152606916 abstract "Innovative treatment modalities are needed for Ewing's sarcoma (ES), a neoplasm with a disappointingly low survival rate despite the use of aggressive multimodal therapeutic approaches. We and others (D. Yee et al., J. Clin. Investig., 86: 1806-1814, 1990; K. Scotlandi et al., Cancer Res., 56: 4570-4574, 1996) have previously shown the existence and the pathogenetic relevance of an autocrine loop, mediated by the insulin-like growth factor-I receptor (IGF-IR), which is crucial for survival and proliferation of ES cells in vitro. Moreover, we reported that the IGF-IR-blocking monoclonal antibody (MAb), alphaIR3, as well as suramin, a drug that can interfere with growth factor by binding to the receptors, inhibited both the tumorigenic and the metastatic ability of ES cells in athymic mice. In this study, we analyzed whether agents that can block the IGF-IR-mediated loop are of value in association with conventional cytotoxic drugs for the design of more effective therapeutic regimens. Both alphaIR3 MAb and suramin treatment significantly increased the antitumor in vitro effects of doxorubicin and vincristine, two drugs with a leader action on ES. These findings were obtained by both simultaneous and sequential treatments. Analysis of the proliferation rate and of apoptosis revealed that alphaIR3 MAb and suramin significantly enhanced the G(1)-phase rate induced by doxorubicin, without substantially affecting doxorubicin-G(2)-M-blockage of cell cycle, and significantly increased the induction of apoptosis, which confirmed that the specific blockage of IGF-IR deprives ES cells of an important tool for the prevention of drug-induced apoptosis. Moreover, combination treatments of doxorubicin plus alphaIR3 MAb significantly increase the doxorubicin-induced impairment of the ability of ES cells to form colonies in soft agar. In conclusion, we showed that, in ES, the blockage of IGF-IR by a neutralizing MAb or by suramin may greatly potentiate the antitumor activity of conventional chemotherapeutic drugs." @default.
• W2152606916 created "2016-06-24" @default.
• W2152606916 creator A5005486608 @default.
• W2152606916 creator A5006421587 @default.
• W2152606916 creator A5013677367 @default.
• W2152606916 creator A5015636061 @default.
• W2152606916 creator A5026002068 @default.
• W2152606916 creator A5035392874 @default.
• W2152606916 creator A5043283322 @default.
• W2152606916 creator A5068376072 @default.
• W2152606916 creator A5083948167 @default.
• W2152606916 creator A5085277690 @default.
• W2152606916 date "2001-06-01" @default.
• W2152606916 modified "2023-09-25" @default.
• W2152606916 title "Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells." @default.
• W2152606916 cites W1522008678 @default.
• W2152606916 cites W1562838305 @default.
• W2152606916 cites W1595424043 @default.
• W2152606916 cites W1600831499 @default.
• W2152606916 cites W1764997248 @default.
• W2152606916 cites W1794538072 @default.
• W2152606916 cites W1827870815 @default.
• W2152606916 cites W1832906656 @default.
• W2152606916 cites W1848388033 @default.
• W2152606916 cites W1971251657 @default.
• W2152606916 cites W1977499961 @default.
• W2152606916 cites W1987577319 @default.
• W2152606916 cites W2007535339 @default.
• W2152606916 cites W2013523350 @default.
• W2152606916 cites W2016711993 @default.
• W2152606916 cites W2038809726 @default.
• W2152606916 cites W2054711858 @default.
• W2152606916 cites W2070839077 @default.
• W2152606916 cites W2104135564 @default.
• W2152606916 cites W2124825512 @default.
• W2152606916 cites W2130788909 @default.
• W2152606916 cites W2143011127 @default.
• W2152606916 cites W2156807752 @default.
• W2152606916 cites W2160466713 @default.
• W2152606916 cites W2166585583 @default.
• W2152606916 cites W2213019416 @default.
• W2152606916 cites W3121869049 @default.
• W2152606916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11410521" @default.
• W2152606916 hasPublicationYear "2001" @default.
• W2152606916 type Work @default.
• W2152606916 sameAs 2152606916 @default.
• W2152606916 citedByCount "32" @default.
• W2152606916 countsByYear W21526069162012 @default.
• W2152606916 countsByYear W21526069162013 @default.
• W2152606916 countsByYear W21526069162014 @default.
• W2152606916 countsByYear W21526069162015 @default.
• W2152606916 countsByYear W21526069162019 @default.
• W2152606916 countsByYear W21526069162020 @default.
• W2152606916 countsByYear W21526069162023 @default.
• W2152606916 crossrefType "journal-article" @default.
• W2152606916 hasAuthorship W2152606916A5005486608 @default.
• W2152606916 hasAuthorship W2152606916A5006421587 @default.
• W2152606916 hasAuthorship W2152606916A5013677367 @default.
• W2152606916 hasAuthorship W2152606916A5015636061 @default.
• W2152606916 hasAuthorship W2152606916A5026002068 @default.
• W2152606916 hasAuthorship W2152606916A5035392874 @default.
• W2152606916 hasAuthorship W2152606916A5043283322 @default.
• W2152606916 hasAuthorship W2152606916A5068376072 @default.
• W2152606916 hasAuthorship W2152606916A5083948167 @default.
• W2152606916 hasAuthorship W2152606916A5085277690 @default.
• W2152606916 hasConcept C126322002 @default.
• W2152606916 hasConcept C128240485 @default.
• W2152606916 hasConcept C142724271 @default.
• W2152606916 hasConcept C154317977 @default.
• W2152606916 hasConcept C159654299 @default.
• W2152606916 hasConcept C170493617 @default.
• W2152606916 hasConcept C190283241 @default.
• W2152606916 hasConcept C202751555 @default.
• W2152606916 hasConcept C203014093 @default.
• W2152606916 hasConcept C2775960820 @default.
• W2152606916 hasConcept C2776182878 @default.
• W2152606916 hasConcept C2776694085 @default.
• W2152606916 hasConcept C2776755627 @default.
• W2152606916 hasConcept C2777586341 @default.
• W2152606916 hasConcept C2778256501 @default.
• W2152606916 hasConcept C2779429289 @default.
• W2152606916 hasConcept C2780689927 @default.
• W2152606916 hasConcept C2781303535 @default.
• W2152606916 hasConcept C502942594 @default.
• W2152606916 hasConcept C542903549 @default.
• W2152606916 hasConcept C55493867 @default.
• W2152606916 hasConcept C71924100 @default.
• W2152606916 hasConcept C86803240 @default.
• W2152606916 hasConcept C98274493 @default.
• W2152606916 hasConceptScore W2152606916C126322002 @default.
• W2152606916 hasConceptScore W2152606916C128240485 @default.
• W2152606916 hasConceptScore W2152606916C142724271 @default.
• W2152606916 hasConceptScore W2152606916C154317977 @default.
• W2152606916 hasConceptScore W2152606916C159654299 @default.
• W2152606916 hasConceptScore W2152606916C170493617 @default.
• W2152606916 hasConceptScore W2152606916C190283241 @default.
• W2152606916 hasConceptScore W2152606916C202751555 @default.
• W2152606916 hasConceptScore W2152606916C203014093 @default.

• next